U.S. Markets open in 3 hrs 8 mins
  • S&P Futures

    4,618.00
    +51.75 (+1.13%)
     
  • Dow Futures

    34,744.00
    +287.00 (+0.83%)
     
  • Nasdaq Futures

    16,365.75
    +215.25 (+1.33%)
     
  • Russell 2000 Futures

    2,242.50
    +45.20 (+2.06%)
     
  • Crude Oil

    68.97
    +2.79 (+4.22%)
     
  • Gold

    1,788.10
    +11.60 (+0.65%)
     
  • Silver

    22.93
    +0.12 (+0.53%)
     
  • EUR/USD

    1.1334
    -0.0005 (-0.0453%)
     
  • 10-Yr Bond

    1.4430
    0.0000 (0.00%)
     
  • Vix

    23.82
    +6.71 (+39.22%)
     
  • GBP/USD

    1.3317
    +0.0016 (+0.1185%)
     
  • USD/JPY

    113.3550
    +0.1750 (+0.1546%)
     
  • BTC-USD

    56,948.34
    -206.43 (-0.36%)
     
  • CMC Crypto 200

    1,465.65
    -2.28 (-0.16%)
     
  • FTSE 100

    7,152.08
    +92.63 (+1.31%)
     
  • Nikkei 225

    27,935.62
    +113.86 (+0.41%)
     

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2020 and Highlights Corporate Progress

  • Oops!
    Something went wrong.
    Please try again later.
·13 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2021 and highlighted corporate progress.

Corporate Progress

  • Exclusive Licensing Agreement for GIAPREZA™ (Angiotensin II) and XERAVA™ (Eravacycline) in Europe: In January 2021, La Jolla Pharmaceutical Company announced that it and certain of its wholly owned subsidiaries (collectively, La Jolla) entered into an exclusive licensing agreement with PAION AG and its wholly owned subsidiary (collectively, PAION) to commercialize GIAPREZA and XERAVA in the European Economic Area, the United Kingdom and Switzerland (the Territories). Under the terms of the exclusive licensing agreement, La Jolla is entitled to receive: (i) an upfront cash payment of $22.5 million; (ii) potential commercial milestone payments of up to $109.5 million; and (iii) double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA.

  • Acquisition of Tetraphase Pharmaceuticals, Inc. (Tetraphase): In July 2020, La Jolla completed its acquisition of Tetraphase, a biopharmaceutical company focused on commercializing its novel tetracycline, XERAVA, to treat serious and life-threatening infections. Financial results for periods ending December 31, 2020 and beyond include Tetraphase’s financial results subsequent to the acquisition closing date of July 28, 2020.

  • Net Sales: For the three and twelve months ended December 31, 2020, net sales were $11.0 million and $33.4 million, respectively, compared to $7.3 million and $23.1 million, respectively, for the same periods in 2019.

    • GIAPREZA Net Sales: For the three and twelve months ended December 31, 2020, GIAPREZA U.S. net sales were $8.7 million and $29.3 million, respectively, up 19% and 27%, respectively, from the same periods in 2019.

    • XERAVA Net Sales: Subsequent to July 28, 2020 and through December 31, 2020, XERAVA U.S. net sales were $4.2 million. For the three and twelve months ended December 31, 2020, including the period prior to the acquisition of Tetraphase, XERAVA U.S. net sales were $2.3 million and $8.2 million, respectively, up 53% and 128%, respectively, from the same periods in 2019.

"2020 was a productive year for La Jolla as we completed the integration of Tetraphase, increased net sales of both products compared to the prior year and reduced our operating costs," said Larry Edwards, President and Chief Executive Officer of La Jolla. "Our agreement with PAION positions us well to serve the needs of patients suffering from life-threatening diseases in both the U.S. and Europe. As we enter 2021, our focus will be on continuing to grow net sales of both GIAPREZA and XERAVA while continuing to manage operating costs."

Financial Results

For the three and twelve months ended December 31, 2020, net sales were $11.0 million and $33.4 million, respectively, compared to $7.3 million and $23.1 million, respectively, for the same periods in 2019.

La Jolla’s net loss for the three and twelve months ended December 31, 2020 was $3.5 million and $39.4 million, or $0.13 and $1.44 per share, respectively, compared to $25.2 million and $116.5 million, or $0.93 per share and $4.30 per share, respectively, for the same periods in 2019.

As of December 31, 2020, La Jolla had $21.2 million of cash and cash equivalents. On a pro forma basis, adjusting for $18.9 million of upfront net proceeds from its licensing agreement with PAION, net of the amounts due under the George Washington University and Harvard University license agreements, La Jolla had cash and cash equivalents of $40.1 million.

Net cash used for operating activities for the three and twelve months ended December 31, 2020 was $7.3 million and $37.6 million, respectively, down 57% and 56%, respectively, from the same periods in 2019. Net cash used for operating activities for the three and twelve months ended December 31, 2020, excluding cash expenditures related to reductions in headcount and transaction costs associated with the Tetraphase acquisition, was $5.7 million and $27.2 million, respectively, down 65% and 67%, respectively, from the same periods in 2019. Cash expenditures related to reductions in headcount were $1.6 million and $9.5 million for the three and twelve months ended December 31, 2020, respectively, and $0.9 million and $3.2 million, respectively, for the same periods in 2019. Cash expenditures related to transaction costs associated with the Tetraphase acquisition were zero and $0.9 million for the three and twelve months ended December 31, 2020, respectively.

About GIAPREZA

GIAPREZA™ (angiotensin II) injection is approved by the U.S. Food and Drug Administration (FDA) as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. GIAPREZA is approved by the European Commission (EC) for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. GIAPREZA mimics the body’s endogenous angiotensin II peptide, which is central to the renin-angiotensin-aldosterone system, which in turn regulates blood pressure. Prescribing information for GIAPREZA is available at http://www.giapreza.com. The European Summary of Product Characteristics is available on the EMA website: www.ema.europa.eu/en/medicines/human/EPAR/giapreza. GIAPREZA is marketed in the U.S. by La Jolla Pharmaceutical Company on behalf of La Jolla Pharma, LLC, its wholly owned subsidiary, and will be marketed in Europe by PAION AG on behalf of La Jolla Pharma, LLC.

GIAPREZA Important Safety Information

Contraindications

None.

Warnings and Precautions

There is a potential for venous and arterial thrombotic and thromboembolic events in patients who receive GIAPREZA. Use concurrent venous thromboembolism (VTE) prophylaxis.

Adverse Reactions

The most common adverse reactions that were reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events.

Drug Interactions

Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see Full Prescribing Information for the United States and the Summary of Product Characteristics for the European Union.

About XERAVA

XERAVA™ (eravacycline) for injection is approved by the U.S. Food and Drug Administration (FDA) as a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in patients 18 years of age and older. XERAVA is approved by the European Commission (EC) for the treatment of cIAI in adults. Prescribing information for XERAVA is available at www.xerava.com. XERAVA is marketed in the U.S. by Tetraphase Pharmaceuticals, Inc., a wholly owned subsidiary of La Jolla, and will be marketed in Europe by PAION AG on behalf of Tetraphase Pharmaceuticals, Inc.

XERAVA Important Safety Information

XERAVA is a tetracycline class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.

XERAVA is not indicated for the treatment of complicated urinary tract infections.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

XERAVA is contraindicated for use in patients with known hypersensitivity to eravacycline, tetracycline-class antibacterial drugs or to any of the excipients. Life-threatening hypersensitivity (anaphylactic) reactions have been reported with XERAVA.

The use of XERAVA during tooth development (last half of pregnancy, infancy and childhood to the age of eight years) may cause permanent discoloration of the teeth (yellow-gray-brown) and enamel hypoplasia.

The use of XERAVA during the second and third trimester of pregnancy, infancy and childhood up to the age of eight years may cause reversible inhibition of bone growth.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range in severity from mild diarrhea to fatal colitis.

The most common adverse reactions observed in clinical trials (incidence ≥ 3%) were infusion site reactions, nausea and vomiting.

XERAVA is structurally similar to tetracycline-class antibacterial drugs and may have similar adverse reactions. Adverse reactions including photosensitivity, pseudotumor cerebri and anti-anabolic action, which has led to increased blood urea nitrogen, azotemia, acidosis, hyperphosphatemia, pancreatitis and abnormal liver function tests, have been reported for other tetracycline-class antibacterial drugs, and may occur with XERAVA. Discontinue XERAVA if any of these adverse reactions are suspected.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

For additional information, please see Full Prescribing Information for the United States.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases. GIAPREZA™ (angiotensin II) is approved by the U.S. FDA as a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. XERAVA™ (eravacycline) is approved by the U.S. FDA for the treatment of complicated intra-abdominal infections. For more information, please visit www.ljpc.com.

Forward-looking Statements

This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: GIAPREZA™ (angiotensin II) and XERAVA™ (eravacycline) sales; whether La Jolla will realize the benefits from the acquisition of Tetraphase Pharmaceuticals, Inc.; regulatory actions relating to La Jolla’s products by the U.S. FDA, European Commission and/or other regulatory authorities; expected future cash flows of La Jolla, including milestone and/or royalty payments resulting from La Jolla’s exclusive license agreement with PAION AG; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.

LA JOLLA PHARMACEUTICAL COMPANY

Condensed Consolidated Balance Sheets

(in thousands, except par value and share amounts)

December 31,

December 31,

2020

2019

ASSETS

Current assets:

Cash and cash equivalents

$

21,221

$

87,820

Accounts receivable, net

5,834

2,960

Inventory, net

6,013

2,211

Prepaid expenses and other current assets

3,388

4,467

Total current assets

36,456

97,458

Goodwill

20,123

-

Intangible assets, net

14,873

-

Right-of-use lease assets

536

15,491

Property and equipment, net

215

18,389

Restricted cash

40

909

Total assets

$

72,243

$

132,247

LIABILITIES AND SHAREHOLDERS’ DEFICIT

Current liabilities:

Accounts payable

$

2,762

$

4,177

Accrued expenses

6,494

9,312

Accrued payroll and related expenses

2,878

8,332

Lease liabilities, current portion

204

2,766

Total current liabilities

12,338

24,587

Deferred royalty obligation, net

124,437

124,379

Accrued interest expense on deferred royalty obligation, less current portion

19,111

12,790

Lease liabilities, less current portion

332

26,481

Other noncurrent liabilities

4,112

-

Total liabilities

$

160,330

$

188,237

Commitments and contingencies (Note 6)

Shareholders’ deficit:

Common Stock, $0.0001 par value; 100,000,000 shares authorized, 27,402,648 and 27,195,469 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively

3

3

Series C-12 Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at December 31, 2020 and December 31, 2019; and liquidation preference of $3,906 at December 31, 2020 and December 31, 2019

3,906

3,906

Additional paid-in capital

984,756

977,432

Accumulated deficit

(1,076,752

)

(1,037,331

)

Total shareholders’ deficit

(88,087

)

(55,990

)

Total liabilities and shareholders’ deficit

$

72,243

$

132,247

LA JOLLA PHARMACEUTICAL COMPANY

Condensed Consolidated Statements of Operations

(in thousands, except per share amounts)

Year Ended

December 31,

2020

2019

Revenue

Net product sales

$

33,419

$

23,054

Total revenue

33,419

23,054

Operating expenses

Cost of product sales

7,819

2,392

Selling, general and administrative

38,428

45,134

Research and development

23,010

85,329

Total operating expenses

69,257

132,855

Loss from operations

(35,838

)

(109,801

)

Other income (expense)

Interest expense

(10,051

)

(10,774

)

Interest income

235

2,128

Other income—related party

6,279

1,939

Other income (expense)

(46

)

-

Total other income (expense), net

(3,583

)

(6,707

)

Net loss

$

(39,421

)

$

(116,508

)

Net loss per share, basic and diluted

$

(1.44

)

$

(4.30

)

Weighted-average common shares outstanding, basic and diluted

27,329

27,112

LA JOLLA PHARMACEUTICAL COMPANY

Condensed Consolidated Statements of Cash Flows

(Unaudited)

(in thousands)

Year Ended

December 31,

2020

2019

Operating activities

Net loss

$

(39,421

)

$

(116,508

)

Adjustments to reconcile net loss to net cash used for operating activities:

Share-based compensation expense

6,207

23,733

Depreciation expense

2,188

4,552

Non-cash interest expense

6,379

8,775

Inventory fair value step-up adjustment included in cost of product sales

2,458

-

Amortization of intangible assets

647

-

Change in fair value of contingent value rights

(800

)

-

Amortization of right-of-use lease assets

1,249

1,307

Loss on short-term investments

502

-

Loss on disposal of property and equipment, net of gain on lease termination

10

24

Changes in operating assets and liabilities:

Accounts receivable, net

(1,687

)

(1,579

)

Inventory, net

(1,493

)

(191

)

Prepaid expenses and other current assets

2,297

644

Accounts payable

(2,815

)

(4,395

)

Accrued expenses

(5,781

)

395

Accrued payroll and related expenses

(5,454

)

823

Lease liabilities

(2,126

)

(2,530

)

Net cash used for operating activities

(37,640

)

(84,950

)

Investing activities

Acquisition of Tetraphase, net of cash, cash equivalents and restricted cash acquired

(33,513

)

-

Purchases of short-term investments

(2,999

)

-

Purchases of property and equipment

-

(698

)

Proceeds from the sale of property and equipment

3,070

-

Proceeds from the sale of short-term investments

2,497

-

Net cash used for investing activities

(30,945

)

(698

)

Financing activities

Net proceeds from issuance of common stock under 2013 Equity Plan

605

31

Net proceeds from issuance of common stock under ESPP

512

833

Net cash provided by financing activities

1,117

864

Net decrease in cash, cash equivalents and restricted cash

(67,468

)

(84,784

)

Cash, cash equivalents and restricted cash, beginning of period

88,729

173,513

Cash, cash equivalents and restricted cash, end of period

$

21,261

$

88,729

Supplemental disclosure of non-cash investing and financing activities

Initial recognition of right-of-use lease asset

$

536

$

16,798

Conversion of Series F Convertible Preferred Stock into common stock

$

-

$

2,737

Cumulative-effect adjustment from adoption of ASU 2018-07

$

-

$

(160

)

Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets

Cash and cash equivalents

$

21,221

$

87,820

Restricted cash

40

909

Total cash, cash equivalents and restricted cash

$

21,261

$

88,729

View source version on businesswire.com: https://www.businesswire.com/news/home/20210308005193/en/

Contacts

Michael Hearne
Chief Financial Officer
La Jolla Pharmaceutical Company
(858) 333-5769
mhearne@ljpc.com